Ceralasertib: tested with established drugs
24 studies: they are given beside it. Page 1 of 1. Open to participants first (4), then studies with results posted, then the rest; newest registration first within each.
- Using Biomarker Tests to Select and Test New, Personalized Treatments for Extensive Stage Small Cell Lung Cancer, PRISM StudyRecruitingNCT06769126Phase 2Report a problem
- Phase II Study of Radiotherapy Followed by Durvalumab and Ceralasertib in Stage III NSCLC Patients With Thoracic Relapses +/- Oligometastases After PACIFIC RegimenRecruitingNCT06680050Phase 2Report a problem
- Restoring Sensitivity To Immunotherapy In Advanced Triple Negative Breast Cancer Exploiting Ceralasertib Priming Followed By Combined Durvalumab/Nab-PaclitaxelRecruitingNCT05582538Phase 2Report a problem
- AZD6738 Plus Durvalumab in Biliary Tract CancerRecruitingNCT04298008Phase 2Report a problem
- A Study of Ceralasertib Monotherapy and Ceralasertib Plus Durvalumab in Patients With Melanoma and Resistance to PD-(L)1 InhibitionActive, not recruitingNCT05061134Phase 2Results postedReport a problem
- Olaparib With Ceralasertib in Recurrent OsteosarcomaActive, not recruitingNCT04417062Phase 2Results postedReport a problem
- Testing Olaparib and AZD6738 in IDH1 and IDH2 Mutant TumorsActive, not recruitingNCT03878095Phase 2Results postedReport a problem
- Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)Active, not recruitingNCT03787680Phase 2Results postedReport a problem
- Combination ATR and PARP Inhibitor (CAPRI) Trial With AZD6738 and Olaparib in Recurrent Ovarian CancerCompletedNCT03462342Phase 2Results postedReport a problem
- Human ADME Study of [14C]-Ceralasertib (AZD6738) and Absolute Bioavailability of CeralasertibTerminatedNCT06754761Phase 1Report a problem
- Testing the Addition of AZD6738 (Ceralasertib) to Immunotherapy to Increase Time Without Cancer for Patients With Non-Small Cell Lung CancerActive, not recruitingNCT06732401Phase 3Report a problem
- A Study to Investigate Efficacy and Safety of Ceralasertib Plus Durvalumab in Participants Aged ≥ 18 Years With Advanced or Metastatic Non-small Cell Lung Cancer Whose Disease Progressed on or After Prior Anti-PD-(L)1 Therapy and Platinum-based ChemotherapyActive, not recruitingNCT05941897Phase 2Report a problem
- A Study to Evaluate the Safety and Pharmacokinetics of Ceralasertib in Combination With Durvalumab in Chinese Patients With Advanced Solid TumoursActive, not recruitingNCT05514132Phase 1Report a problem
- A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based ChemotherapyActive, not recruitingNCT05450692Phase 3Report a problem
- Testing the Combination of Two Anti-cancer Drugs, DS-8201a and AZD6738, for The Treatment of Advanced Solid Tumors Expressing the HER2 Protein or Gene, The DASH TrialActive, not recruitingNCT04704661Phase 1Report a problem
- Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung CancerActive, not recruitingNCT04699838Phase 2Report a problem
- DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract CancerActive, not recruitingNCT04298021Phase 2Report a problem
- ATr Inhibitor in Combination With Olaparib/Durvalumab (MEDI4736) in Gynaecological Cancers With ARId1A Loss or no LossActive, not recruitingNCT04065269Phase 2Report a problem
- A Study of AZD6738 in Combination With Durvalumab in Patients With Refractory Solid Tumors (Cohort A: Chemotherapy-Refractory Gastric Cancer; Cohort B: Anti-PD(L)Active, not recruitingNCT03780608Phase 2Report a problem
- Ceralasertib (AZD6738) Alone and in Combination With Olaparib or Durvalumab in Patients With Solid TumorsActive, not recruitingNCT03682289Phase 2Report a problem
- AZD6738 & Gemcitabine as Combination TherapyStatus unknownNCT03669601Phase 1Report a problem
- Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]CompletedNCT03428607Phase 2Report a problem
- A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT03328273Phase 1Report a problem
- Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory CancerCompletedNCT02630199Phase 1Report a problem